Information  X 
Enter a valid email address

Astrazeneca PLC OrdShs USD0.25 (AZN)

Date Time Source Announcement
18 Sep 2019 7:00 am
RNS
AstraZeneca amends collaboration with Ironwood
09 Sep 2019 8:38 am
RNS
Imfinzi is first immunotherapy to show both
04 Sep 2019 7:11 am
RNS
Tagrisso approved in China as a 1st-line treatment
02 Sep 2019 3:00 pm
RNS
Total Voting Rights
  7:05 am
RNS
Brilinta reduced the risk of cardiovascular events
  7:00 am
RNS
Detailed results from Phase III DAPA-HF trial
29 Aug 2019 7:00 am
RNS
Anifrolumab Phase III trial meets primary endpoint
28 Aug 2019 7:05 am
RNS
Fasenra granted US Orphan Drug Designation for
  7:00 am
RNS
Breztri Aerosphere Phase III ETHOS trial met
22 Aug 2019 7:00 am
RNS
Roxadustat approved in China for the treatment of
  7:00 am
RNS
AstraZeneca agrees to buy US FDA Priority Review
21 Aug 2019 7:00 am
RNS
Update on the Phase III NEPTUNE trial
20 Aug 2019 7:00 am
RNS
Farxiga met primary endpoint in landmark Phase III
19 Aug 2019 7:00 am
RNS
Directorate Change
14 Aug 2019 7:00 am
RNS
Lynparza Phase III PAOLA-1 trial met primary endpo
  7:00 am
RNS
Calquence granted US Breakthrough Therapy Designat
09 Aug 2019 9:28 am
RNS
Amendment: Tagrisso significantly improves overall
  7:00 am
RNS
Tagrisso significantly improves overall survival
07 Aug 2019 7:00 am
RNS
Lynparza Phase III PROfound trial in HRR*
05 Aug 2019 7:00 am
RNS
Forxiga label updated in the EU in type-2 diabetes
01 Aug 2019 3:00 pm
RNS
Total Voting Rights
25 Jul 2019 7:00 am
RNS
AZN: H1 2019 Results
15 Jul 2019 7:00 am
RNS
Update on US regulatory decision for Farxiga
12 Jul 2019 7:00 am
RNS
Imfinzi granted US Orphan Drug Designation for
01 Jul 2019 3:00 pm
RNS
Total Voting Rights
  7:00 am
RNS
Forxiga receives positive EU CHMP opinion for
  7:00 am
RNS
Fasenra receives positive EU CHMP opinion for self
27 Jun 2019 7:00 am
RNS
Imfinzi improves overall survival at interim
19 Jun 2019 7:00 am
RNS
Breztri Aerosphere (PT010) approved in Japan for
  7:00 am
RNS
Lynparza approved in Japan for 1st-line
  7:00 am
RNS
Bevespi Aerosphere approved by the Japanese
18 Jun 2019 7:00 am
RNS
Lynparza approved in the EU for 1st-line
17 Jun 2019 7:00 am
RNS
Calquence significantly prolonged the time patient
12 Jun 2019 4:45 pm
RNS
Publication of a Prospectus
06 Jun 2019 7:00 am
RNS
Calquence Phase III ELEVATE-TN trial met primary
05 Jun 2019 12:36 pm
EQS
AstraZeneca: Where has all the cash gone?
03 Jun 2019 3:00 pm
RNS
Block listing Interim Review
  3:00 pm
RNS
Total Voting Rights
  7:00 am
RNS
Lynparza nearly doubled time patients lived with
10 May 2019 7:00 am
RNS
Pooled analyses of the roxadustat global Phase III
08 May 2019 2:00 pm
RNS
Director/PDMR Shareholding
  11:00 am
RNS
Director Declaration
  7:00 am
RNS
Trastuzumab deruxtecan demonstrated clinically
07 May 2019 7:00 am
RNS
Calquence PhIII ASCEND trial met primary endpoint
03 May 2019 7:00 am
RNS
Qternmet XR approved in the US for type-2 diabetes
01 May 2019 3:00 pm
RNS
Total Voting Rights
  12:00 pm
RNS
Director/PDMR Shareholding
29 Apr 2019 7:00 am
RNS
Lynparza receives positive EU CHMP opinion for 1st
26 Apr 2019 5:45 pm
RNS
Result of AGM
  7:00 am
RNS
AZN: Q1 2019 Results
10 Apr 2019 7:00 am
RNS
Lynparza approved in EU for the treatment of germl
09 Apr 2019 4:10 pm
EQS
Global Pharmaceuticals: 2018 industry sales
04 Apr 2019 1:30 pm
RNS
Holding(s) in Company
03 Apr 2019 10:00 am
RNS
Director/PDMR Shareholding
02 Apr 2019 3:00 pm
RNS
Total Voting Rights
01 Apr 2019 6:00 pm
RNS
Astrazeneca
  3:00 pm
RNS
Total Voting Rights
  7:00 am
RNS
Selumetinib gets Breakthrough Therapy Designation
29 Mar 2019 5:15 pm
RNS
Results of Placing
 
Headlines
Top categories
Company finder

a d v e r t i s e m e n t